HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prospective association of psychological pain and hopelessness with suicidal thoughts.

AbstractBACKGROUND:
Early markers preceding suicide ideation (SI) may provide valuable information for both assessment and treatment. The glutamatergic modulator ketamine has rapid, transient effects on SI, creating an opportunity to observe potential antecedents of the re-emergence of SI. This analysis evaluated whether the interaction between two suicide risk factors-psychological pain and hopelessness-were prospectively associated with SI post-ketamine administration.
METHODS:
Data were drawn from three ketamine clinical trials of participants with treatment-resistant major depressive disorder or bipolar disorder (n = 108) with short- and/or long-term follow-up (three or 11 days). A random intercept cross-lagged panel model evaluated the longitudinal relationship between the correlated concepts, specifically whether the interaction between hopelessness and psychological pain was associated with future SI.
RESULTS:
Psychological pain and hopelessness were not prospectively associated with SI in short-term or long-term analyses; rather, long-term analyses found that SI was associated with later psychological pain and hopelessness. Similarly, no relationship was observed for other suicide risk factors, including anhedonia, depressed mood, and impaired sleep.
LIMITATIONS:
Secondary analysis of clinical trial data not collected for this purpose; hopelessness and psychological pain were assessed via proxy measures from existing depression rating scales; the small sample size required a restricted statistical model.
CONCLUSIONS:
Psychological pain and hopelessness were not associated with the re-emergence of SI post-ketamine. These results may be due to limited variability in the data. The re-emergence of SI post-ketamine may also not follow patterns typically seen in non-pharmacologic contexts. Individuals with a history of SI warrant careful monitoring post-ketamine administration.
AuthorsElizabeth D Ballard, Cristan A Farmer, Jessica Gerner, Bartholt Bloomfield-Clagett, Lawrence T Park, Carlos A Zarate Jr
JournalJournal of affective disorders (J Affect Disord) Vol. 308 Pg. 243-248 (07 01 2022) ISSN: 1573-2517 [Electronic] Netherlands
PMID35429526 (Publication Type: Journal Article)
CopyrightPublished by Elsevier B.V.
Chemical References
  • Ketamine
Topics
  • Depressive Disorder, Major (drug therapy, psychology)
  • Depressive Disorder, Treatment-Resistant (drug therapy)
  • Humans
  • Ketamine (therapeutic use)
  • Pain (drug therapy)
  • Suicidal Ideation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: